Liver cancer due to NASH
3Curable in someAI-generated
NASH liver cancer: curable early, but cases risingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.
Milestones
dot size = significanceWhat's being tested now
Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.
See all 1205 active Fatty Liver trials on Clin2 →Where we are
AI-generatedLiver cancer from NASH is curable in some patients, especially those diagnosed early and eligible for surgery, transplant, or local ablation. For advanced disease, approved drugs like sorafenib, cabozantinib, and tremelimumab extend survival but are not curative. Resmetirom treats NASH, not liver cancer. Deaths have been rising over recent decades, though newer therapies are improving outcomes.
- Can NASH-related liver cancer be cured?
- Yes, if caught early and treated with surgery, transplant, or ablation. Cure is unlikely once cancer spreads.
- What treatments exist for advanced disease?
- Approved systemic therapies—sorafenib, cabozantinib, tremelimumab—prolong life but are not curative.
- Is resmetirom a treatment for liver cancer?
- No. Resmetirom treats NASH itself, not liver cancer. It may reduce risk but is not a cancer therapy.
- Are death rates from this cancer rising?
- Yes, due to increasing NASH prevalence. However, newer drugs are starting to improve survival.
- How many clinical trials are underway?
- Over 1,200 trials are active, including 72 in phase 3, offering hope for better treatments.